Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals.
Level 5 - mechanism / opinion, no new human data
Narrative review based on biochemical mechanisms and physiological theory without primary human data or systematic review methodology.
PubMed 15466951 · doi:10.1080/07315724.2004.10719389
What was done
This narrative review compared the biochemical pathways, enzymatic mechanisms, and functional cardiovascular effects of magnesium with HMG-CoA reductase inhibitors (statins) using existing literature.
What was found
The abstract reports that large trials show statins lower LDL-cholesterol by 35% to 65% and reduce cardiovascular events and mortality. It describes magnesium as a required cofactor for the enzyme that deactivates HMG-CoA reductase, an essential component for lecithin cholesterol acyltransferase (which lowers LDL-cholesterol and triglycerides while raising HDL-cholesterol) and desaturase, and an endogenous calcium channel blocker. No quantitative clinical trial data or effect sizes are provided for magnesium administration.
Why it matters
The review outlines how magnesium acts as a physiological controller of lipid synthesis at enzymatic points shared with or complementary to statin therapy.
Limits
The abstract describes a narrative review of biochemical mechanisms without providing direct comparative trial data, sample sizes, or clinical outcome measurements for magnesium supplementation.
Cited by
- supports Excess calcium causes muscle contraction, hypertension, and heart attacks, and magnesium controls calcium and mitigates calcium crystal buildup in damaged heart tissue.